Vinay Prasad Returns to FDA to Resume Oversight of Vaccine, Gene Therapy, and Blood Product Regulation
Vinay Prasad is making a comeback at the Food and Drug Administration to once again take the reins in overseeing vaccine, gene therapy, and blood product regulation. This decision comes after the FDA requested Prasad to resume his leadership role at the Center for Biologics Evaluation and Research, as confirmed by Health and Human Services spokesman Andrew Nixon.
While it remains unclear if Prasad will also continue to serve as the FDA’s chief medical and scientific officer, his return marks a significant development in the agency’s leadership. Just two weeks ago, Prasad had left the FDA amidst growing tensions surrounding a gene therapy product for Duchenne’s muscular dystrophy produced by Sarepta Therapeutics. Additionally, right-wing influencer Laura Loomer had launched a campaign criticizing Prasad for his self-description as a liberal in previous posts.
Prasad’s expertise and experience in the field of biologics evaluation and research make him a valuable asset to the FDA. His return is expected to bring stability and continuity to the agency’s efforts in regulating critical medical products such as vaccines, gene therapies, and blood products.
For more in-depth coverage and analysis on this topic, subscribe to STAT+ to unlock exclusive articles and daily intelligence on Capitol Hill and the life sciences industry. Stay informed and stay ahead with STAT+.
